Kissei Pharmaceutical Co., Ltd. has sublicensed the development and marketing rights of the acute myeloid leukemia treatment Ortacitinib in Taiwan to Orient Europharma Co., Ltd., and expects to receive upfront payments and milestone fees.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4547","jir_company_name":"Kissei Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-01","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4547-20260501-01.pdf","jir_short_summary":"Kissei Pharmaceutical Co., Ltd. has sublicensed the development and marketing rights of the acute myeloid leukemia treatment Ortacitinib in Taiwan to Orient Europharma Co., Ltd., and expects to receive upfront payments and milestone fees.","jir_summary":"### Contract Overview\nKissei Pharmaceutical Co., Ltd. has entered into a sublicense agreement granting development and marketing rights of the acute myeloid leukemia treatment Ortacitinib to Orient Europharma Co., Ltd. in Taiwan. Under this agreement, OEP will conduct development and commercialization in Taiwan, while Kissei Pharmaceutical will receive upfront and milestone payments and supply formulations. OEP is also the licensee for Kissei\u2019s diabetes treatment Glufast\u24c7 in Taiwan, establishing a long-term collaborative relationship.\n\n### Outlook and Earnings Guidance\nThe consolidated earnings forecast for the fiscal year ending March 2027, reflecting the impact of this agreement, will be disclosed at the financial results announcement for the fiscal year ending March 2026 scheduled on May 11, 2026. Kissei Pharmaceutical will continue to collaborate with its partners to advance development in licensed territories and accelerate early patient access to Ortacitinib.","jir_financial_highlights":"Upfront and Milestone Income: Undisclosed (Undisclosed)\nOrtacitinib Development and Marketing Rights Region: Taiwan (New Contract)\nContract Signing Date: 2026-05-01 (New)","jir_category":"","jir_hashtags":"#KisseiPharmaceutical, #M&A, #NewDrugLicensing, #JapaneseStocks","jir_key_figures":"Contract Signing Date: 2026-05-01\nTarget Drug: Acute Myeloid Leukemia Treatment Ortacitinib\nLicensee: Orient Europharma Co., Ltd. (Taiwan)","jir_meta_title":"[Kissei Pharmaceutical] Signing of Licensing Agreement for Acute Myeloid Leukemia Treatment in Taiwan\uff5cMay 2026","jir_meta_description":"Kissei Pharmaceutical has signed a sublicense agreement with Orient Europharma Co., Ltd. for development and marketing rights of the acute myeloid leukemia treatment Ortacitinib in Taiwan. Upfront and milestone payments are expected.","jir_og_title":"[Kissei Pharmaceutical] Signing of Licensing Agreement for Acute Myeloid Leukemia Treatment in Taiwan","jir_og_description":"Kissei Pharmaceutical has granted development and marketing rights of Ortacitinib in Taiwan to Orient Europharma Co., Ltd., with upfront and milestone payments expected.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":8930,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"m_and_a_alliance","footnotes":""},"sector":[],"importance":[],"class_list":["post-44764","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n